The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

• On Jan. 19, the FDA granted Rare Pediatric Disease Designation to Mesoblast's Revascor® for treating children with congenital heart disease. The company’s stock fell around 16% over the past month and has a 52-week low of $1.61 .
• RSI Value: 29.61
• MESO Price Action: Shares of Mesoblast rose 1.1% to close at $1.79 on Thursday.

• On Jan. 9, Neogen reported second-quarter FY24 sales of $229.6 million, down 0.2% Y/Y, missing the consensus of $232.87 million. Core revenue declined 0.9%. The company revised its FY24 revenue guidance to $935 million-$955 million, versus prior guidance of $955 million-$985 million and consensus of $960.65 million. The company’s stock fell around 21% over the past month and has a 52-week low of $14.44.
• RSI Value: 29.75
• NEOG Price Action: Shares of Neogen fell 1% to close at $16.20 on Thursday.

• On Jan. 25, Humana reported a fourth-quarter adjusted EPS loss of 11 cents, a turnaround from EPS income of $1.97 a year ago, missing the consensus of 5 cents. Humana announced its initial fiscal year 2024 EPS outlook of ‘approximately $14.87’ on a GAAP basis, ‘and approximately $16.00’ on an adjusted basis (versus consensus of $28.91). The company’s shares lost around 14% over the past five days. The company’s 52-week low is $342.69.
• RSI Value: 19.43
• HUM Price Action: Shares of Humana fell 11.7% to close at $355.36 on Thursday.